Micromet's blinatumomab data to be presented at two upcoming medical meetings

May 23 2011

Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at two upcoming medical meetings:

European Hematology Association Annual Congress
June 9 - 12, 2011, London, UK
Abstract title: Clinical activity of the anti-CD19 BiTE blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL): Interim results of a phase 2 study
Abstract number: 844
Presentation date and time: Saturday, June 11, 5:30 - 6:45 PM GMT
First author: Max Topp, MD, University of Wuerzburg, Wuerzburg, Germany

11^th International Congress on Malignant Lymphoma
June 15 - 18, 2011, Lugano, Switzerland
Abstract title: Blinatumomab (CD3/CD19 BiTE antibody) results in a high response rate in patients with relapsed non-Hodgkin's lymphoma (NHL) including MCL and DLBCL
Abstract number: 068
Presentation date and time: Thursday, June 16, 2:45 - 3 PM CET
First author: Marie Elisabeth Goebeler, MD, University of Wuerzburg, Wuerzburg, Germany